Zubair Ahmed, MD
Interventional Cardiology · Fayetteville, ARNPI 1831386556
Payments from drug & device makers
Across 737 payments — averaging $49.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$13K
- Medtronic$7K
- Abbott$6K
- Penumbra, Inc.$3K
- Abiomed$1K
- Philips North America LLC$820
- plus $6K from 34 others
What the payments were for
- Travel & lodging$18,63551%
- Food & beverage$17,74449%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 27 | $12,966 |
| Medtronic(2 entities) | 337 | $6,826 |
| Abbott | 93 | $5,820 |
| Penumbra, Inc. | 16 | $3,020 |
| Abiomed | 13 | $1,167 |
| Philips North America LLC | 8 | $820 |
| Amgen | 35 | $685 |
| Pfizer | 54 | $659 |
| Edwards Lifesciences | 6 | $597 |
| Inari Medical, Inc. | 4 | $524 |
| Novartis | 41 | $524 |
| Shockwave Medical, Inc | 3 | $396 |
| Cvrx, Inc. | 2 | $386 |
| E.r. Squibb & Sons, L.L.C. | 16 | $258 |
| Johnson & Johnson | 19 | $216 |
| Biosense Webster, Inc. | 5 | $192 |
| Alnylam Pharmaceuticals Inc. | 3 | $142 |
| Bard Peripheral Vascular, Inc. | 1 | $121 |
| AstraZeneca | 9 | $120 |
| Boston Scientific | 2 | $120 |
| Livanova USA, Inc. | 1 | $89 |
| Stryker | 3 | $87 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $84 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $78 |
| Astellas Pharma US Inc | 4 | $65 |
| Merck | 3 | $61 |
| Avinger Inc. | 2 | $48 |
| Asahi Intecc USA, Inc. | 4 | $48 |
| Boehringer Ingelheim | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Lundbeck LLC | 3 | $41 |
| Amarin Pharma, Inc. | 3 | $39 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Novo Nordisk | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAEOTOM Alpha$10,084
- COREVALVE EVOLUT R$2,519
- Indigo System$2,464
- MitraClip$1,811
- TRICLIP$1,402
- Impella$923
- CoreValve Evolut$772
- Azurion 7 M20$577
- FLOWTRIEVER CATHETER, S$511
- CT THROMBECTOMY SYSTEM KIT$511
- ClosureFast$489
- Penumbra System$402
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$396
- Barostim Neo System$386
- Artis icono floor$376
- JETi Peripheral Catheter$278
- ESPRIT$257
- Repatha$226
- COROFLOW$179
- Micra$169
How this compares
$36,419 in reported general payments places this provider in the 90th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 420 | $420,419 |
| EntrestoSacubitril/Valsartan | 163 | $180,535 |
| XareltoRivaroxaban | 125 | $123,954 |
| BrilintaTicagrelor | 64 | $39,314 |
| FarxigaDapagliflozin Propanediol | 21 | $30,922 |
| Repatha SureclickEvolocumab | 32 | $28,756 |
| JardianceEmpagliflozin | 13 | $18,906 |
| MultaqDronedarone Hcl | 39 | $12,058 |
| Repatha SyringeEvolocumab | 14 | $8,483 |
| Ranolazine ErRanolazine | 83 | $6,007 |
| Dofetilide | 42 | $4,494 |
| Atorvastatin Calcium | 411 | $3,104 |
| Metoprolol Succinate | 211 | $2,763 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 230 | $2,457 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 130 | $2,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $659 | $420,419420 claims |
| NovartisEntresto | $524 | $180,535163 claims |
| Johnson & JohnsonXarelto | $216 | $123,954125 claims |
| AstraZenecaBrilinta, Farxiga | $120 | $70,23785 claims |
| Boehringer IngelheimJardiance | $47 | $18,90613 claims |
| Sanofi-aventis U.S. LLCMultaq | $46 | $12,05839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Fayetteville
- Joel CarverFayetteville$305K
- Salik NazirFayetteville$19K
- Shaun SenterFayetteville$8K
- Gaurav DharLittle Rock$793K
- Ernesto Ruiz-RodriguezLittle Rock$499K
- Vasili LendelLittle Rock$206K
- Vijay RajaLittle Rock$106K
- Thomas WattsLittle Rock$79K
- Lena AwarJonesboro$43K
- Stephen BroughtonLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.